SAN CARLOS, Calif., Dec. 10, 2025 /PRNewswire/ -- Siolta Therapeutics, a biotechnology company developing first-in-class live biotherapeutic products (LBPs), today announced that its abstract ...

DANVILLE, Calif.--(BUSINESS WIRE)--Nexilico, a pioneer in precision microbiome engineering, and Siolta Therapeutics, a leader in the development of live biotherapeutic products (LBPs), have entered ...

WASHINGTON, July 17, 2019 /PRNewswire/ -- The Microbiome Therapeutics Innovation Group (MTIG) announced today the addition of Siolta Therapeutics to its coalition of companies leading the research and ...

SAN CARLOS, Calif.--(BUSINESS WIRE)--Siolta Therapeutics, a clinical-stage biotech company, announced today it has raised $30M in a series B investment round to support the clinical development of its ...

STMC-103H exhibited 64% reduction in the risk of atopic dermatitis in subjects who completed one year of treatment with strong and consistent effects across multiple efficacy endpoints and was safe ...

SAN CARLOS, Calif.--(BUSINESS WIRE)--Siolta Therapeutics, a clinical-stage biopharmaceutical company developing novel microbiome-based targeted therapeutics, today announced that it was awarded an ...

Siolta Therapeutics, a clinical-stage biotech company developing first-in-class live biotherapeutic products (LBPs), announced positive top-line results from the phase 2 ADORED study (Allergic Disease ...